Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 7:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 537 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF) Clear all
Completed Phase 2 Interventional

2-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES)

NCT00483067
View directory record Official record
Conditions
Leukemia
Interventions
2-CdA, Ara-C, G-CSF (Granulocyte colony-stimulating factor)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 76 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2012 · Synced Oct 14, 2026, 7:41 AM EDT
Completed Phase 2 Interventional Results available

Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

NCT00425477
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
sargramostim, bexarotene, cytogenetic analysis, fluorescence in situ hybridization, flow cytometry, laboratory biomarker analysis, biopsy
Biological · Drug · Genetic + 2 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2018 · Synced Oct 14, 2026, 7:41 AM EDT
Completed Phase 2 Interventional Results available

Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Patients With Locally Recurrent or Metastatic Breast Cancer

NCT00266110
View directory record Official record
Conditions
Breast Cancer
Interventions
sargramostim, therapeutic autologous dendritic cells, trastuzumab, vinorelbine ditartrate
Biological · Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 12, 2018 · Synced Oct 14, 2026, 7:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT

NCT03018223
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, Acute Leukemia in Remission, Chronic Myeloid Leukemia, Primary Myelofibrosis, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Hodgkin Lymphoma, Multiple Myeloma
Interventions
Fludarabine, Busulfan, Cyclophosphamide, Total body irradiation (TBI), Peripheral Blood Hematopoietic Cell Transplantation (HCT), Sirolimus (SIR), Mycophenolate mofetil (MMF), Granulocyte-colony stimulating factor (G-CSF)
Drug · Radiation · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Oct 14, 2026, 7:41 AM EDT
Completed Phase 1 Interventional

GM-CSF Before Surgery in Treating Patients With Localized Prostate Cancer

NCT00305669
View directory record Official record
Conditions
Prostate Cancer
Interventions
sargramostim, immunohistochemistry staining method, immunological diagnostic method, laboratory biomarker analysis, conventional surgery, neoadjuvant therapy
Biological · Other · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2014 · Synced Oct 14, 2026, 7:41 AM EDT
Completed Phase 1 Interventional

Leukine (Sargramostim) for Parkinson's Disease

NCT01882010
View directory record Official record
Conditions
Parkinson's Disease
Interventions
sargramostim, placebo, Sham Comparator: Controls
Drug · Diagnostic Test
Lead sponsor
University of Nebraska
Other
Eligibility
35 Years to 85 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 6, 2023 · Synced Oct 14, 2026, 7:41 AM EDT
Terminated Not applicable Interventional Results available

G-CSF PMRD: Granulocyte Colony Stimulating Factor (G-CSF) Stimulated Bone Marrow and In Vivo T-Cell Depletion in Patients With Hematologic Malignancies or Bone Marrow Failure Syndrome

NCT00228813
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
Granulocyte Colony Stimulating Factor
Drug
Lead sponsor
Emory University
Other
Eligibility
Up to 22 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Oct 14, 2026, 7:41 AM EDT
Completed Phase 1 Interventional

Vaccine Therapy and Sargramostim in Treating Patients With Non-small Cell Lung Cancer

NCT00005630
View directory record Official record
Conditions
Lung Cancer
Interventions
ras peptide cancer vaccine, sargramostim
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
17 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 14, 2026, 7:41 AM EDT
Completed Phase 1 Interventional Results available

A Pilot Study of Vaccination With Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate Cancer

NCT00972309
View directory record Official record
Conditions
Prostate Specific Antigens, Prostate Neoplasms
Interventions
T-cell receptor alternate reading frame protein (TARP) peptide vaccine, T-cell receptor alternate reading frame protein (TARP) dendritic cell vaccine
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years · Male only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Oct 14, 2026, 7:41 AM EDT
Completed Phase 2 Interventional

Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) for Patients With Rising Prostate-Specific Antigen (PSA)

NCT00678054
View directory record Official record
Conditions
Prostate Cancer
Interventions
GM-CSF
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2015
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 23, 2017 · Synced Oct 14, 2026, 7:41 AM EDT
Withdrawn Phase 2 Interventional

Trial to Evaluate Safety and Efficacy of GM-CSF /Sargramostim in Down Syndrome

NCT05482334
View directory record Official record
Conditions
Down Syndrome
Interventions
Sargramostim for Injection, Saline Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 35 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Oct 14, 2026, 7:41 AM EDT
Completed Phase 2 Interventional

Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial Disease

NCT03304821
View directory record Official record
Conditions
Peripheral Artery Disease (PAD)
Interventions
GM-CSF, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
21 Years to 85 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 14, 2026, 7:41 AM EDT
Completed Phase 1Phase 2 Interventional Results available

RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia

NCT00968253
View directory record Official record
Conditions
Leukemia, Acute Lymphocytic Leukemia
Interventions
Everolimus (RAD001), Cyclophosphamide, Vincristine, Doxorubicin, Dexamethasone, Mesna, Methotrexate, Ara-C (Cytarabine), Methylprednisone, G-CSF
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
10 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 27, 2019 · Synced Oct 14, 2026, 7:41 AM EDT
Completed Phase 2 Interventional Results available

Immuno-Augmentation With GM-CSF of Pneumococcal Vaccine in Chronic Lymphocytic Leukemia Patients

NCT00323557
View directory record Official record
Conditions
Leukemia
Interventions
Sargramostim (GM-CSF), Pneumococcal Vaccine
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 5, 2012 · Synced Oct 14, 2026, 7:41 AM EDT
Terminated Phase 2 Interventional

Personalized Active Immunotherapy (Vaccine Therapy) and Sargramostim Given After Standard of Care Treatment With Rituximab and Chemotherapy for Initial Treatment With Lymphoma

NCT00510471
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
autologous immunoglobulin idiotype-KLH conjugate vaccine
Drug
Lead sponsor
Genitope Corporation
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
9
States / cities
Los Angeles, California • Denver, Colorado • Indianapolis, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2008 · Synced Oct 14, 2026, 7:41 AM EDT
Completed Phase 2 Interventional

Vaccine Therapy and Biological Therapy in Treating Patients With Advanced Cancer

NCT00019084
View directory record Official record
Conditions
Breast Cancer, Cervical Cancer, Colorectal Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer
Interventions
aldesleukin, mutant p53 peptide pulsed dendritic cell vaccine, ras peptide cancer vaccine, sargramostim, therapeutic autologous lymphocytes, therapeutic tumor infiltrating lymphocytes
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 14, 2026, 7:41 AM EDT
Terminated Not applicable Interventional Results available

Busulfan and Cyclophosphamide Followed By ALLO BMT

NCT01685411
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Allopurinol, Keppra, Busulfan, Cyclophosphamide, Tacrolimus, Mycophenolate mofetil, Allogeneic hematopoietic stem cell transplant, Filgrastim, antithymocyte globulin
Drug · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 44 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Oct 14, 2026, 7:41 AM EDT
Completed Phase 1 Interventional Results available

MIBG With Dinutuximab +/- Vorinostat

NCT03332667
View directory record Official record
Conditions
Neuroblastoma
Interventions
131I-MIBG, Dinutuximab, Vorinostat, Sargramostim, Potassium Iodide
Radiation · Drug
Lead sponsor
New Approaches to Neuroblastoma Therapy Consortium
Other
Eligibility
1 Year to 30 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2025 · Synced Oct 14, 2026, 7:41 AM EDT
Completed Phase 2 Interventional Results available

A Randomized Trial of GM-CSF in Patients With ALI/ARDS

NCT00201409
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult
Interventions
Placebo, GM-CSF
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 90 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
3
States / cities
Denver, Colorado • Atlanta, Georgia • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 29, 2015 · Synced Oct 14, 2026, 7:41 AM EDT
Terminated Phase 2 Interventional Results available

Phase II Study of Fludarabine and Mitoxantrone, Followed by GM-CSF(Granulocyte-macrophage Colony-stimulating Factor) and Rituximab

NCT00208975
View directory record Official record
Conditions
Lymphoma
Interventions
Mitoxantrone/Cyclophosphamide, Fludarabine, Rituximab and GM-CSF
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 28, 2012 · Synced Oct 14, 2026, 7:41 AM EDT
Completed Early Phase 1 Interventional

Vaccine Therapy in Treating Patients With Previously Treated Stage II or Stage III Breast Cancer

NCT00640861
View directory record Official record
Conditions
Breast Cancer
Interventions
CpG oligodeoxynucleotide, HER-2/neu peptide vaccine, MUC-1 peptide vaccine, incomplete Freund's adjuvant, sargramostim, immunoenzyme technique, immunologic technique
Biological · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 31, 2018 · Synced Oct 14, 2026, 7:41 AM EDT
Completed Phase 1 Interventional

Liposomal Doxorubicin Plus Combination Chemotherapy in Treating Patients With AIDS-Associated Non-Hodgkin's Lymphoma

NCT00004162
View directory record Official record
Conditions
Lymphoma
Interventions
sargramostim, methotrexate, pegylated liposomal doxorubicin hydrochloride, vincristine sulfate
Biological · Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 12, 2013 · Synced Oct 14, 2026, 7:41 AM EDT
Completed Phase 2 Interventional Results available

Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia

NCT00038610
View directory record Official record
Conditions
Leukemia
Interventions
Imatinib Mesylate, Cyclophosphamide, Doxorubicin, Vincristine, Dexamethasone, Methotrexate, Cytarabine, Mesna, G-CSF
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2015 · Synced Oct 14, 2026, 7:41 AM EDT
Completed Phase 1 Interventional

Adoptive Transfer of MART1/Melan-A CTL for Malignant Melanoma

NCT00512889
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
therapeutic autologous lymphocytes, Use of an artificial antigen presenting cell (aAPC) to generate CTL, GM-CSF, Irradiation of cutaneous tumor lesion
Biological · Genetic · Drug + 1 more
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 1, 2013 · Synced Oct 14, 2026, 7:41 AM EDT